$$XID NIHGUIDE 19920110 V21N01 P2O2 ************************************ multimodality treatment for optimal management of all stages and presentations of disease, but these treatment methods cause serious morbidity and fail to cure most patients with advanced disease. In preclinical cancer treatment research, there is an urgent need to translate recent developments in the molecular biology of cancer into the discovery of new anticancer treatments whose actions will be highly specific for particular genes or gene products. Exciting areas that may be exploited include oncogenes such as the HER-2/neu oncogene in breast cancer, suppressor genes, signal transduction, cell cycle regulation, growth factors/receptors, metastasis, and angiogenesis. Several approaches will be necessary to take advantage of these new opportunities. Additional topics include, but are not limited to, drug discovery of new anticancer agents, biochemical and molecular mechanisms of antitumor drug action, and pharmacology and toxicology of antitumor agents. Studies to circumvent individual and multiple drug resistance and prevent metastasis of these cancers to other organs are included. Clinical research opportunities exist in the areas of high-dose chemotherapy followed by autologous bone marrow rescue, multidrug resistance, radiosensitizers, adjuvant chemotherapy, innovative surgical or multimodality approaches, particle beam irradiation, novel immune therapies and genetic manipulations of host or malignant tissues, therapy with biological products, such as interleukins, monoclonal antibodies, and/or retinoic acid. Applications that address these opportunities and these particular tumors are specifically solicited. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements are required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis must be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions that disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale must be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information must be included in the form PHS 398 in Section 2, A-D of the Research Plan AND summarized in Section 2, E. Human Subjects. Applicants/offerors are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans (including American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups must be provided. For the purpose of this policy, clinical research is defined as human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the review will be deferred until the information is provided. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. APPLICATION PROCEDURES Applications must be submitted on the grant application form PHS 398 (rev. 10/88, reprinted 9/89) and will be accepted at the standard application deadlines as indicated in the application kit. Application kits are available at most institutional business offices and may be obtained from the Office of Grants Inquiries, Division of Research Grants, Westwood Building, Room 449, National Institutes of Health, Bethesda, MD 20892, telephone 301/496-7441. The title and number of the announcement must be typed in line 2 on the face page of the application. The completed original application and six legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW PROCEDURES Applications will be assigned on the basis of established Public Health Service referral guidelines. Applications will be reviewed for scientific and technical merit by study sections of the Division of Research Grants, NIH, in accordance with the standard NIH peer review procedures. Following scientific-technical review, the applications will receive a second-level review by an appropriate national advisory council or board. Applications for supplements to ongoing awards will be reviewed according to procedures applicable to the mechanism of the ongoing award. AWARD CRITERIA Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Program balance among research areas of the announcement INQUIRIES Written and telephone inquiries concerning the objectives and scope of this program announcement are encouraged and must be directed to the NCI Referral Office at the address below. The opportunity to clarify any issues or questions from potential applicants is welcome. NCI Referral Office Review Logistics Branch Division of Extramural Activities National Cancer Institute Westwood Building, Room 850 Bethesda, MD 20892 Telephone: (301) 496-7173 FAX: (301) 402-0275 Inquiries will be referred to the appropriate NCI Program Director in one of the program Divisions noted above in the "Research Objectives" section of this announcement. Direct inquiries regarding fiscal matters to: Ms. Roslyn Bacon Grants Administration Specialist Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 6120 Executive Boulevard Bethesda, MD 20892 Telephone: (301) 496-7800, extension 51 FAX: (301) 496-8601 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance under one or more of the applicable sections: No. 93.393, No. 93.394, No. 93.395, No. 93.396, and No. 93.399. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$P2 END ************************************************************ $$P3 BEGIN PA-92-28 ************************************************* ACADEMIC RESEARCH ENHANCEMENT AWARD PA: PA-92-28 P.T. 34; K.W. 0710030, 0404000, 1014006 National Institutes of Health Application Receipt Date: June 19, 1991 PURPOSE The National Institutes of Health (NIH) is making a special effort to stimulate research in educational institutions that provide baccalaureate training for a significant number of the Nation's research scientists but that historically have not been major recipients of NIH support. Since Fiscal Year (FY) 1985, Congressional appropriations for the NIH have included funds for this initiative, the Academic Research Enhancement Award (AREA) Program (R15). The AREA funds are intended to support new research projects or expand ongoing research activities proposed by faculty members of eligible institutions in areas related to the health sciences. Applications received in June 1991 for AREA grants to be awarded in FY 1992 are currently undergoing review for scientific merit. Since it is anticipated that additional funds will be available next year, the NIH is inviting grant applications at this time for AREA grants to be awarded competitively in FY 1993. ELIGIBILITY Applicant Institutions o All domestic institutions offering baccalaureate or advanced degrees in the sciences related to health are eligible, EXCEPT those that have received an NIH Biomedical Research Support Grant (BRSG) of $20,000 or more per year for four or more years during the period from FY 1985 through FY 1991. o Health professional schools (e.g., schools of medicine, dentistry, nursing, osteopathy, pharmacy, veterinary medicine, public health, allied health, and optometry) as well as organizationally discrete campuses of a university system, are eligible if they meet the above criterion. o Several applications proposing different research projects may be submitted by an applicant institution. Proposed Principal Investigators o Must not have active research grant support (including an AREA) from either NIH or the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) at the time of award of an AREA grant. o May not submit a traditional NIH or ADAMHA research grant (R01) application for essentially the same project as a pending AREA application. o Are expected to conduct the majority of their research at their own institution, although limited access to special facilities or equipment at another institution is permitted. o May not be awarded more than one AREA grant at a time nor be awarded a second AREA grant to continue the research initiated under the first AREA grant. Those in doubt about eligibility should consult the Office of Sponsored Programs at the institution. Questions regarding eligibility, policies, procedures, and other administrative aspects of the NIH AREA Program that remain AFTER CONSULTATION WITH THE INSTITUTIONAL OFFICE may be addressed to: Research Training and Special Programs Office, NIH, Building 31, Room 5B44, Bethesda, MD 20892, telephone (301) 496-1968. APPLICATION PROCEDURES Applications for the AREA Program will be accepted under the application submission procedures of the Division of Research Grants (DRG), NIH. The research grant application form PHS 398, Revised 9/91, must be used in applying for an AREA grant. Applicants must obtain the AREA Program Guidelines containing supplemental instructions for AREA applications from the Office of Grants Inquiries, DRG, NIH (see address below). These instructions must be followed in preparing an application. AREA grants are awarded on a competitive basis. Applicants may request support for up to $75,000 for direct costs (plus applicable indirect costs) for a period not to exceed 36 months. No more than $35,000 may be requested for direct costs for any one year. Although this award is non-renewable, it will enable qualified individual scientists within the eligible institutions to receive support for feasibility studies, pilot studies, and other small-scale research projects preparatory to seeking more substantial funding from the NIH research grant programs. REVIEW PROCEDURES Applications for the AREA Program will be subjected to the standard peer review process involving two sequential levels of review. The first level of review is performed by initial review groups composed primarily of non-Federal scientists selected for their competence in particular scientific fields. The second level of review is made by the National Advisory Council or Board of the NIH awarding component to which the grant application has been assigned by the DRG. These groups are composed of both scientific and lay representatives who are chosen for their expertise, interest, or activity in matters related to the mission of the individual awarding component. Council or Board recommendations are based on both scientific merit and relevance to awarding component program goals. In general, the NIH may award a grant only if the corresponding application has been recommended for funding by both levels of review. AWARD DETERMINATION Funding decisions will be based on the proposed research project's scientific merit and relevance to NIH programs and the institution's contribution to the undergraduate preparation of doctoral-level health professionals. Among projects of essentially equivalent scientific merit and program relevance, preference will be given to those submitted by institutions that have granted baccalaureate degrees to 25 or more individuals who have obtained academic or professional doctoral degrees in the health related sciences during the period 1982-1991. SUPPLEMENTAL INSTRUCTIONS/APPLICATION FORMS Those individuals and institutions meeting the eligibility requirements may contact the office named below to receive the AREA Program Guidelines and/or form PHS 398 application packages. (NOTE: Form PHS 398, Revised 9/91, is currently being printed. It should be available in institutional business offices and from the NIH by March 1992.) AREA Office of Grants Inquiries Division of Research Grants National Institutes of Health Westwood Building, Room 449 Bethesda, MD 20892 Telephone: (301) 496-7441 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance, No. 93.390. Grants will be awarded under authority of the Public Health Service Act, Title III, Section 301 (Public Law 78- 410, as amended; 42 USC 241) and administered in accordance with the PHS Grants Policy Statement and Federal Regulations at 42 CFR Part 52 and 42 CFR Part 74. $$P3 END ************************************************************ $$P4 BEGIN PA-92-29 ************************************************* INTERACTIVE RESEARCH PROJECT GRANTS FOR CANCER PA: PA-92-29 P.T. 34; K.W. 0715035, 0710070, 0760025, 0745027, 0755015, 0755025 National Cancer Institute Application Receipt Dates: February 1, June 1, and October 1 PURPOSE Complex questions in cancer research often require investigative efforts that extend beyond the level practicable in a single project or that require a mixture of technical approaches beyond the means of a single investigator. The perceived merit of individual research project (R01) applications sometimes may be limited by the lack of a comprehensive, interdisciplinary approach, or by limitations in resident technical expertise. There also may be areas of investigation that are under-represented in applications because they cannot effectively be exploited without a collaborative effort, yet local opportunities for such interactions are not available. The National Cancer Institute (NCI), under an Interactive Research Project Grant (IRPG) announcement, seeks to encourage the coordinated submission of related research project grant applications from investigators who want to collaborate on a common cancer research theme, but do not require extensive shared physical resources or core functions. A minimum of three independent investigators with related research objectives are encouraged to submit concurrent, collaborative, cross-referenced individual research project grant applications (R01) that share a common research focus. Applications may be from either a single institution or a consortium of institutions. Applications will be reviewed independently for scientific merit. Meritorious applications will be considered for funding both as independent awards and in the context of the overall proposed collaboration. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Program Announcement, Interactive Research Project Grants for Cancer, is related to the priority area of cancer. Potential applicants may obtain a copy of a "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). BACKGROUND INFORMATION Historically, the NCI has relied on multi-component awards, such as program projects (P01) and Cancer Center Support grants (P30), to encourage interdisciplinary collaborations in areas requiring integration and central direction of basic and clinical research components. A hallmark of such awards is the provision for extensive core facilities/resources and appointment of a program director to manage the overall effort. For many research areas it may be more appropriate to consider an intermediate level of collaboration, less extensive than that described above, but beyond that practical for single projects. For such intellectually driven collaborative efforts, the exchange of data, materials, and ideas, rather than shared physical resources or central oversight, is the primary requirement. The concept of IRPGs set forth in this announcement is meant to address and facilitate this class of research activities. Typically, the IRPG approach will be suited to many basic research questions as well as research to develop, apply, and evaluate interventions for cancer prevention and control. The IRPG mechanism may also fit well with clinical applications that propose limited testable research questions or with focused phase I and II therapeutic and related correlative laboratory studies. Applicants will benefit from use of the IRPG mechanism by establishing a larger framework of reference for the proposed work, by facilitating formal collaborations tailored to achieving research objectives, by providing a record of independently acquired awards credited to each funded investigator, and by allowing retention of research autonomy by the named Principal Investigator on each of the interactive grants. Each grantee will have the ability to submit on his/her own behalf competing supplements as appropriate to incorporate promising new directions of research as they evolve. The freedom to establish collaborations on an equal footing at separate sites (including foreign locations), and the improved transferability of awards made to individual Principal Investigators, also are significant benefits. In contrast, translational research programs that span a variety of disciplines and programs that require extensive co-located core resources, would continue to be served best by traditional multi-component program award mechanisms. RESEARCH GOALS AND SCOPE The NCI encourages qualified investigators to develop and submit concurrently coordinated research project applications that address areas of relevance to cancer in which the interactive research project concept may be applied. Applications submitted as a package should be tightly focused and the interactions and benefits of the proposed linkages should be made explicit as explained below. IRPG applications will be accepted in any relevant area of cancer research where this mechanism may be constructively applied. Some typical (non-exhaustive) examples are cited below: o Immunobiology of specific cancers, such as breast, ovarian, and prostate cancer. Since these cancers involve both immune and neuroendocrine responses, projects requiring expertise in various aspects of cancer biology, immunology, and/or endocrinology will be needed for a comprehensive approach for these questions. o Hormones and signalling pathways. Basic science projects may be combined that integrate multiple aspects of hormonal regulation of cancer from growth factors to receptors to signal transduction to genetic regulation. o Detection and intervention studies in breast and other cancers. New methods are needed to promote the use of detection methodologies in populations at risk and to measure the efficacy and compliance with recommendations. Studies to identify and overcome barriers to health promotion and to measure cost-effectiveness may also be linked to such a program. o Focused studies on phase I and II clinical trials. Projects designed to investigate promising combined therapeutic approaches to a single type of cancer may be linked with correlative laboratory investigations to investigate further the mode of action and/or biological effects of treatments. o Related basic studies focused on multiple facets of common viral or chemical carcinogenic agents such as HIV or human papilloma virus, that do not require extensive core resources. o Basic drug discovery programs that focus on multiple aspects of a related class of compounds or on a single mechanism of action. o Methodologically related applications that focus on development and/or application of specific methodologies to cancer research, where extensive shared physical resources are not required. o Research on variations in control of the cell cycle that operate specifically in tumor cells. Projects might focus on unique enzymes or effector molecules, the role of protein modifications such as phosphorylation, activation of oncogenes, and interactions with suppressor genes. Prospective applicants are encouraged to explore other areas of potential for the IRPG mechanism with NCI program directors. MECHANISM OF SUPPORT AND SPECIAL INSTRUCTIONS Support of this program will be by the research project (R01) grant. Applicants will be responsible for the planning, direction, and execution of the proposed projects. One Principal Investigator out of the group MUST be identified as the "Program Coordinator," and must be cited in all applications on page 2 of form PHS 398. Individual investigators may request funds for the time and effort contributed toward the coordination of the overall research and for collaborative resource activities. Each application MUST be complete in itself, with all appropriate approvals, budgets, and signatures. Each application MUST be identified by checking "yes" on line 2 of the PHS 398 face page and citing this announcement, "Interactive Research Project Grants for Cancer, PA-92-XX." The use of the IRPG mechanism must be mentioned briefly in form PHS 398, Sections A-D of the Research plan. The goal of the collaborative efforts MUST be identified in the specific aims of each application, with the major rationale and explanation for the use of the IRPG mechanism to be given in Section G, Consultants/Collaborators. A complete list of applications in the IRPG must be provided in Section G, as well as an indication of the specific collaborations to be established for the individual application under consideration. Requests for limited shared resources, if any, must be proportionally budgeted in each application based on anticipated use, with a full explanation given in the budget. Personnel Time and Effort requests for management of shared resources are allowable. If consortium arrangements between independent institutions are proposed that would make transfer of funds for required new equipment impractical, the entire equipment request may be budgeted by the responsible laboratory. This should be clearly justified. All PHS and NIH grants policies will apply to applications received in response to this announcement. ELIGIBILITY REQUIREMENTS Domestic and foreign non-profit and for-profit organizations and institutions, governments and their agencies, are eligible to apply. Applications may be submitted from a single institution or may include arrangements with multiple institutions if appropriate. Applications from or involving minority institutions, individuals, and women are encouraged. Each application will be considered on its own merit as an individual research project. Therefore, applicants for IRPGs MAY NOT concurrently submit R01 applications that represent significant duplication of the efforts described in the applicant's IRPG. In this regard, it should be noted that the NCI will consider funding meritorious individual IRPG applications if it is not possible to fund the IRPG package as a whole. Concurrent submission of program project (P01) applications that request support for essentially similar work is also prohibited. REVIEW PROCEDURES Upon receipt, applications and supporting material will be reviewed by the Division of Research Grants for completeness. Incomplete applications will be returned without further consideration. Each application will be assigned to an institute on the basis of the scientific subject matter of the application. Therefore, to be eligible for the NCI IRPG program, an application MUST meet the PHS referral guidelines to receive assignment to the NCI. APPLICANTS ARE STRONGLY ENCOURAGED TO CONSULT WITH NCI PROGRAM STAFF PRIOR TO SUBMISSION TO ENSURE THAT THE APPLICATION CONFORMS TO THESE GUIDELINES, AND THAT THE IRPG MECHANISM IS AN APPROPRIATE CHOICE. Complete applications will be reviewed for scientific and technical merit by an appropriate peer review group convened by the Division of Research Grants, NIH. Insofar as possible, assignment of each IRPG application will be to a standing DRG initial review group, that may be supplemented by consultants with additional expertise as required. Investigators should be aware that applications utilizing widely differing approaches will not necessarily be reviewed by the same initial review group. Attention in selecting clearly related applications for submission will aid the process of assignment for review. Initial review groups will employ standard peer review criteria that pertain to all individual research project applications. Following peer review, the applications will receive a second-level review by the National Cancer Advisory Board or other appropriate national advisory council or board. Although there is no fixed set-aside of funds committed to the IRPG mechanism, the NCI will consider for funding all IRPG applications in a cohort if all are rated by peer review as having significant and substantial scientific merit. SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study populations must be described in terms of gender and racial/ethnic group, together with a rationale for its choice. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Section 2, A-D of the Research Plan AND summarized in Section 2, E, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans including American Indians or Alaskan Natives, Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign populations groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants that do not comply with these policies. METHOD OF APPLYING The research grant application form PHS 398 (rev. 10/88) must be used in applying for these grants. Applications will be accepted on the February 1, June 1, and October 1 receipt dates. These forms are available at most institutional business offices; from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Room 449, Westwood Building, Bethesda, MD 20892; and from the NCI Program Director named below. The Program Announcement title and number must be typed on line 2 of the face page. Submit a signed, typewritten original of each application and six signed exact single-sided photocopies to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** **THE MAILING ADDRESS FOR SENDING APPLICATIONS TO THE DIVISION OF RESEARCH GRANTS OR CONTACTING STAFF IN THE WESTWOOD BUILDING IS THE CENTRAL MAILING ADDRESS FOR THE NIH. APPLICANTS WHO USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD BUILDING IS: 5333 Westbard Avenue Bethesda, Maryland 20816 INQUIRIES Written and telephone inquiries concerning the objectives and scope of this Program Announcement and inquiries about whether or not specified proposed research would be appropriate for this mechanism are encouraged and may be directed to: NCI Referral Officer Review Logistics Branch Division of Extramural Activities National Cancer Institute Westwood Building, Room 850 Bethesda, MD 20892 Telephone: (301) 496-7173 FAX: (301) 402-0275 Callers will be referred to the appropriate NCI Program Director. Inquiries regarding fiscal matters may be directed to: Ms. Roslyn Bacon Grants Management Specialist Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 6120 Executive Blvd. Bethesda, MD 20892 Telephone: (301) 496-7800, extension 51 FAX: (301) 496-8601 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance under one or more of the applicable sections: No. 93.393, No. 93.394, No. 93.395, No. 93.396, and No. 93.399. Awards are made under the authorization of the Public Health Service Act, Sections 301, 410, and 411 (Public Law 78-410, 42 USC 241 as amended, Public Law 99-158, 42 USC 285a) and administered under PHS grants policies and Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. $$P4 END ************************************************************